Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1

Plasmodium vivax malaria incidence has increased in Latin America and Asia and is responsible for nearly 74.1% of malaria cases in Latin America. Immune responses to P. vivax are less well characterized than those to P. falciparum, partly because P. vivax is more difficult to cultivate in the labora...

Full description

Bibliographic Details
Main Authors: Bergeline C. Nguemwo Tentokam, Chanaki Amaratunga, Nada A. H. Alani, Nicholas J. MacDonald, David L. Narum, Nichole D. Salinas, Jennifer L. Kwan, Seila Suon, Sokunthea Sreng, Dhelio Batista Pereira, Niraj H. Tolia, Ricardo T. Fujiwara, Lilian L. Bueno, Patrick E. Duffy, Camila H. Coelho
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02295/full
id doaj-2a2ea960972c4d229693fe94357c4687
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Bergeline C. Nguemwo Tentokam
Chanaki Amaratunga
Nada A. H. Alani
Nicholas J. MacDonald
David L. Narum
Nichole D. Salinas
Jennifer L. Kwan
Seila Suon
Sokunthea Sreng
Dhelio Batista Pereira
Niraj H. Tolia
Ricardo T. Fujiwara
Lilian L. Bueno
Patrick E. Duffy
Camila H. Coelho
spellingShingle Bergeline C. Nguemwo Tentokam
Chanaki Amaratunga
Nada A. H. Alani
Nicholas J. MacDonald
David L. Narum
Nichole D. Salinas
Jennifer L. Kwan
Seila Suon
Sokunthea Sreng
Dhelio Batista Pereira
Niraj H. Tolia
Ricardo T. Fujiwara
Lilian L. Bueno
Patrick E. Duffy
Camila H. Coelho
Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
Frontiers in Immunology
malaria
Plasmodium vivax
Pvs230
transmission-blocking vaccine
seroreactivity
author_facet Bergeline C. Nguemwo Tentokam
Chanaki Amaratunga
Nada A. H. Alani
Nicholas J. MacDonald
David L. Narum
Nichole D. Salinas
Jennifer L. Kwan
Seila Suon
Sokunthea Sreng
Dhelio Batista Pereira
Niraj H. Tolia
Ricardo T. Fujiwara
Lilian L. Bueno
Patrick E. Duffy
Camila H. Coelho
author_sort Bergeline C. Nguemwo Tentokam
title Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
title_short Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
title_full Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
title_fullStr Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
title_full_unstemmed Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
title_sort naturally acquired antibody response to malaria transmission blocking vaccine candidate pvs230 domain 1
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2019-10-01
description Plasmodium vivax malaria incidence has increased in Latin America and Asia and is responsible for nearly 74.1% of malaria cases in Latin America. Immune responses to P. vivax are less well characterized than those to P. falciparum, partly because P. vivax is more difficult to cultivate in the laboratory. While antibodies are known to play an important role in P. vivax disease control, few studies have evaluated responses to P. vivax sexual stage antigens. We collected sera or plasma samples from P. vivax-infected subjects from Brazil (n = 70) and Cambodia (n = 79) to assess antibody responses to domain 1 of the gametocyte/gamete stage protein Pvs230 (Pvs230D1M). We found that 27.1% (19/70) and 26.6% (21/79) of subjects from Brazil and Cambodia, respectively, presented with detectable antibody responses to Pvs230D1M antigen. The most frequent subclasses elicited in response to Pvs230D1M were IgG1 and IgG3. Although age did not correlate significantly with Pvs230D1M antibody levels overall, we observed significant differences between age strata. Hemoglobin concentration inversely correlated with Pvs230D1M antibody levels in Brazil, but not in Cambodia. Additionally, we analyzed the antibody response against Pfs230D1M, the P. falciparum ortholog of Pvs230D1M. We detected antibodies to Pfs230D1M in 7.2 and 16.5% of Brazilian and Cambodian P. vivax-infected subjects. Depletion of Pvs230D1M IgG did not impair the response to Pfs230D1M, suggesting pre-exposure to P. falciparum, or co-infection. We also analyzed IgG responses to sporozoite protein PvCSP (11.4 and 41.8% in Brazil and Cambodia, respectively) and to merozoite protein PvDBP-RII (67.1 and 48.1% in Brazil and Cambodia, respectively), whose titers also inversely correlated with hemoglobin concentration only in Brazil. These data establish patterns of seroreactivity to sexual stage Pvs230D1M and show similar antibody responses among P. vivax-infected subjects from regions of differing transmission intensity in Brazil and Cambodia.
topic malaria
Plasmodium vivax
Pvs230
transmission-blocking vaccine
seroreactivity
url https://www.frontiersin.org/article/10.3389/fimmu.2019.02295/full
work_keys_str_mv AT bergelinecnguemwotentokam naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT chanakiamaratunga naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT nadaahalani naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT nicholasjmacdonald naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT davidlnarum naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT nicholedsalinas naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT jenniferlkwan naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT seilasuon naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT sokuntheasreng naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT dheliobatistapereira naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT nirajhtolia naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT ricardotfujiwara naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT lilianlbueno naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT patrickeduffy naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
AT camilahcoelho naturallyacquiredantibodyresponsetomalariatransmissionblockingvaccinecandidatepvs230domain1
_version_ 1725976143654289408
spelling doaj-2a2ea960972c4d229693fe94357c46872020-11-24T21:27:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-10-011010.3389/fimmu.2019.02295485174Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1Bergeline C. Nguemwo Tentokam0Chanaki Amaratunga1Nada A. H. Alani2Nicholas J. MacDonald3David L. Narum4Nichole D. Salinas5Jennifer L. Kwan6Seila Suon7Sokunthea Sreng8Dhelio Batista Pereira9Niraj H. Tolia10Ricardo T. Fujiwara11Lilian L. Bueno12Patrick E. Duffy13Camila H. Coelho14Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Rockville, MD, United StatesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesNational Center for Parasitology, Entomology and Malaria Control, Phnom Penh, CambodiaNational Center for Parasitology, Entomology and Malaria Control, Phnom Penh, CambodiaCentro de Pesquisa em Medicina Tropical, Porto Velho, BrazilLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte, BrazilDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte, BrazilLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, United StatesPlasmodium vivax malaria incidence has increased in Latin America and Asia and is responsible for nearly 74.1% of malaria cases in Latin America. Immune responses to P. vivax are less well characterized than those to P. falciparum, partly because P. vivax is more difficult to cultivate in the laboratory. While antibodies are known to play an important role in P. vivax disease control, few studies have evaluated responses to P. vivax sexual stage antigens. We collected sera or plasma samples from P. vivax-infected subjects from Brazil (n = 70) and Cambodia (n = 79) to assess antibody responses to domain 1 of the gametocyte/gamete stage protein Pvs230 (Pvs230D1M). We found that 27.1% (19/70) and 26.6% (21/79) of subjects from Brazil and Cambodia, respectively, presented with detectable antibody responses to Pvs230D1M antigen. The most frequent subclasses elicited in response to Pvs230D1M were IgG1 and IgG3. Although age did not correlate significantly with Pvs230D1M antibody levels overall, we observed significant differences between age strata. Hemoglobin concentration inversely correlated with Pvs230D1M antibody levels in Brazil, but not in Cambodia. Additionally, we analyzed the antibody response against Pfs230D1M, the P. falciparum ortholog of Pvs230D1M. We detected antibodies to Pfs230D1M in 7.2 and 16.5% of Brazilian and Cambodian P. vivax-infected subjects. Depletion of Pvs230D1M IgG did not impair the response to Pfs230D1M, suggesting pre-exposure to P. falciparum, or co-infection. We also analyzed IgG responses to sporozoite protein PvCSP (11.4 and 41.8% in Brazil and Cambodia, respectively) and to merozoite protein PvDBP-RII (67.1 and 48.1% in Brazil and Cambodia, respectively), whose titers also inversely correlated with hemoglobin concentration only in Brazil. These data establish patterns of seroreactivity to sexual stage Pvs230D1M and show similar antibody responses among P. vivax-infected subjects from regions of differing transmission intensity in Brazil and Cambodia.https://www.frontiersin.org/article/10.3389/fimmu.2019.02295/fullmalariaPlasmodium vivaxPvs230transmission-blocking vaccineseroreactivity